Navigation Links
Cethrin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...ed in December 2006 and amended in March 2007 (the cethrin License) was further amended. The Amendment repla...nd performance-related milestones contained in the cethrin License with a formula-based approach to sharing a...nt for the compounds and technology covered by the cethrin License. In the event that the Company fails to s...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia Alseres Pharmaceuticals, Inc 50...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...ing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pha...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals,...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...yndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...ful, this trial will provide us with evidence that cethrin is more effective than a placebo in treating acute...ur preliminary planning for the Phase IIb trial of cethrin called for us to enroll up to 100 subjects in 80 s...ropriate sites and investigators for the Phase IIb cethrin study expected to commence in the first quarter of...

Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...
Cethrin in Medical Technology

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Boston Life Sciences announced today that clinical data on its lead nerve repair therapy, Cethrin(R), were presented in the Neurotrauma and Critical Care Scientific Sess...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...

Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates

...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
Cethrin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. http://www.alseres.com/ Contact: Kenneth L. Rice 508...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...8, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the cethrin Phase I/IIa trial. -- We are pursuing development and commercialization p... no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. ...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pharmaceut...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...d Injury on the first 37 subjects treated with cethrin at doses up to 6 mg. The data indicated that cethrin was safe and well tolerated. The overall population of patients treated with cethrin demonstrated an improvement in their impairmen...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...tegies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of cethrin and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "antic...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...
Other Tags
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... species may be able to cope with the rising salinity ... The Arctic today is best known for its tundra and ... 53 to 38 million years ago during what is known ... a huge temperate forest with brackish water, home to a ... crocodiles and giant tortoises. Much of what is known about ...
(Date:7/9/2014)... a sparrow-sized fossil from China challenges the commonly held ... gained the ability to fly. The birdlike fossil is ... rather the remains of a tiny tree-climbing animal that ... Dinosaur Museum in Blanding, Utah, and Alan Feduccia of ... Springer,s Journal of Ornithology . , The fossil ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
Other Contents